PATHOLYTIX-GI
PATHOLYTIX: Using Artificial Intelligence to Transform Clinical Diagnostic Pathology
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0PATHOLYTIX-GI project word cloud
Explore the words cloud of the PATHOLYTIX-GI project. It provides you a very rough idea of what is the project "PATHOLYTIX-GI" about.
Project "PATHOLYTIX-GI" data sheet
The following table provides information about the project.
| Coordinator |
DECIPHEX LIMITED
Organization address contact info |
| Coordinator Country | Ireland [IE] |
| Project website | http://www.deciphex.com |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3.1.4. (Active ageing and self-management of health) 2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)) 3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 4. H2020-EU.3.1.6. (Health care provision and integrated care) |
| Code Call | H2020-SMEINST-1-2016-2017 |
| Funding Scheme | SME-1 |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-12-01 to 2018-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | DECIPHEX LIMITED | IE (MORNINGTON MEATH) | coordinator | 50˙000.00 |
Map
Project objective
Routine diagnosis on biopsies and tissues is performed by expert pathologists. However, the pathology sector faces a major crises, due to soaring numbers of biopsies for diagnosis, coupled with decreasing numbers of trained pathologists, which is affecting patients. Technology can alleviate this crises by using computer aided diagnosis (CAD) to increase productivity, reduce costs and streamline workflow.
Deciphex Ltd is an Irish company developing an innovative Computer Aided Diagnosis (CAD) system which will revolutionize the medical diagnosis pathology sector. Our ‘PATHOLYTIX’ system uses state-of-the-art artificial intelligence techniques to automate the laborious and costly pathology assessment (currently done via microscope). By transforming this centuries old clinical practice, we aim to become a market leader in new CAD industry.
We currently have prototype technology and preliminary data, to identify different tissue and cell types. In this feasibility study we will perform pilot studies in a US based clinical pathologist, to demonstrate our tool can identify various diseases. In Phase 2 of the SME Instrument, we will undergo additional development, extensive validation, and build the data management framework and user interface.
There is a large global target market for PATHOLYTIX, which is growing each year driven by an increasing population and higher prevalence of diseases (such as cancer). Hence hospitals and clinics worldwide process hundreds of millions of biopsies per year. With regards to competitors, there is no direct competition. Competitors offer individual components of the pathological workflow, not fit-for-purpose solution like PATHOLYTIX.
Overall, PATHOLYTIX would have a big impact on the pathology sector, by increasing productivity and reducing costs. This should have a knock on effect for the global and EU markets, particularly for patients as diagnosis becomes more efficient.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PATHOLYTIX-GI" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PATHOLYTIX-GI" are provided by the European Opendata Portal: CORDIS opendata.